ClinicalTrials.gg

Program

NNC0471-0119

A development code. Also written as “NNC0471-0119 H”, “NNC0471-0119 A” and “NNC0471-0119 B”.

Its studies are mostly in Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2, led by Novo Nordisk.

Furthest: phase 1, since Oct 28, 20204 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk40 open or runningphase 1since Oct 28, 2020Oct 28, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 28, 2020First study: phase 1 study in Diabetes Mellitus, Type 1First studyNCT04655690 · 48 enrolled · Austria
  2. Feb 21, 2022Phase 1 study in Diabetes Mellitus, Type 1NCT05262595 · 19 enrolled · Austria
  3. Jan 30, 2025Phase 1 study in Diabetes Mellitus, Type 1NCT06809621 · 43 enrolled · Germany
  4. Jul 7, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07068295 · 65 enrolled · Germany

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07068295Diabetes Mellitus, Type 2 · Germany1CompletedFeb 22, 202665
NCT06809621Diabetes Mellitus, Type 1 · Germany1CompletedJul 16, 202543
NCT05262595Diabetes Mellitus, Type 1 · Austria1CompletedAug 29, 202219
NCT04655690Diabetes Mellitus, Type 1 · Austria1CompletedNov 26, 202148

How it is read

Names in the registry

  • “NNC0471-0119 H”, 2 entries
  • “NNC0471-0119 A”, 1 entry
  • “NNC0471-0119 B”, 1 entry
  • “NNC0471-0119 D”, 1 entry
  • “NNC0471-0119”, 1 entry

Codes read as this program: NNC04710119.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
NNC0471-0119 (Novo Nordisk): development program | ClinicalTrials.gg